Cardiotoxicity induced by anthracyclines
Conditions
Interventions
Test group:Qi and Blood Kang Oral Liquid+Chemotherapy
control group:Qi and Blood Kang Oral Liquid Simulator+Chemotherapy
Sponsors
The First Affiliated Hospital of Henan University of Chinese Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: female sex Age range: 18-70 years old; The patient was definitely diagnosed as primary breast cancer; Those who meet the indications for chemotherapy and are ready to receive anthracycline treatment; ECOG score 0-1 expected survival = 6 months; Accept random allocation to the experimental group and control group; Voluntarily participate in the experiment and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Patients with severe cardiac, renal, or hepatic dysfunction, or primary hematopoietic system diseases; Patients who had arrhythmias, NYHA Class III or higher cardiac function, or a relevant history prior to anthracycline administration; Patients who used other cardiotoxic drugs during the treatment period; Patients previously treated with anthracyclines whose dose cannot be traced back; Patients with severe infectious diseases; Patients with consciousness disorders leading to inability to cooperate with the treatment; Patients allergic to any component of the investigational drug or with contraindications to its use; Pregnant or lactating women; Patients currently participating in other clinical drug trials; Patients with diabetes mellitus, impaired fasting glucose, or impaired glucose tolerance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of cardic injury; | — |
Secondary
| Measure | Time frame |
|---|---|
| a-HBDH;BNP;NT-ProBNP;LD;cTnI;LDH;Dynamic ECG;TCM syndrome score;ECOG score;FACT-B score;ck-mb;ck; | — |
Countries
China
Contacts
Public ContactShiqing Jiang
The First Affiliated Hospital of Henan University of Chinese Medicine
Outcome results
None listed